A DRUG TREATMENT that successfully targets a gene involved in skin cancer has been tested for the first time in Sydney patients.
Dz13 safely and effectively turned off a gene that supports tumour growth, and may be useful for treating a huge range of problems, from cancer to macular degeneration.
Turning off the gene then appears to shrink the basal-cell carcinoma skin cancers, said lead researcher Levon Khachigian, the director of the UNSW Centre for Vascular Research. His international research team included scientists from across NSW. It was published in the Lancet medical journal on Tuesday.